Preclinical Development – Chemical
2019 PharmSci 360
Malignant pleural mesothelioma (MPM) is a very aggressive pleura rare cancer, typical of the exposure to asbestos. A novel biodegradable film loaded with cisplatin, for preventing local MPM recurrences after primary tumor surgery, has been studied. The product, developed by start up PlumeStars, is a hydrophilic, thin and flexible film, sufficiently resistant to be intrapleural applied during the removal of primary tumor. It is shucked to mesothelial or epithelial surfaces where it prolongs the anticancer release creating high local concentrations where the residual tumor could develop. In rat disease model, the reduction of tumor recurrence was demonstrated. Despite a higher exposure to drug, very low liver and renal toxic side effects were evidenced in sheep, compared to systemic IV chemotherapy.
Compared to other intracavitary local chemotherapies, using cisplatin film provides a precise and accurate dose applied to the pleura area, releasing on the application site a time controlled amount of drug.